I
Ina Valeria Zurlo
Researcher at Catholic University of the Sacred Heart
Publications - 17
Citations - 50
Ina Valeria Zurlo is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 7 publications receiving 13 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Alessandro Parisi,Alessio Cortellini,Katia Cannita,Olga Venditti,Floriana Camarda,Maria Alessandra Calegari,Lisa Salvatore,Giampaolo Tortora,Giampaolo Tortora,Daniele Rossini,Marco Maria Germani,Alessandra Boccaccino,Emanuela Dell'Aquila,Claudia Angela Maria Fulgenzi,Daniele Santini,Michele De Tursi,Nicola Tinari,Pietro Di Marino,Pasquale Lombardi,Susana Rosello Keranen,Susana Rosello Keranen,Marisol Huerta Alvaro,Ina Valeria Zurlo,Domenico Corsi,Alessandra Emiliani,N. Zanaletti,Teresa Troiani,P. Vitale,Riccardo Giampieri,Filippo Merloni,Mario Occhipinti,Paolo Marchetti,Michela Roberto,Federica Mazzuca,Michele Ghidini,Alice Indini,Ingrid Garajová,Federica Zoratto,Simona Delle Monache,Giampiero Porzio,Corrado Ficorella +40 more
TL;DR: It is revealed that Bevacizumab-based regimens have a slightly better PFS and class-specific AEs profile compared to Aflibercept-based regimen as second-line treatment of RAS wild-type mCRC patients previously treated with anti-EGFR based treatments.
Journal ArticleDOI
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases.
Michele A. Basso,Salvatore Corallo,Maria Alessandra Calegari,Ina Valeria Zurlo,Francesco Ardito,Maria Vellone,Silvio Marchesani,Armando Orlandi,Vincenzo Dadduzio,Giovanni Fucà,Carmela Di Dio,Caterina Mele,Brunella Barbaro,Antonia Strippoli,Alessandro Coppola,Alessandra Cassano,Emilio Bria,Carlo Barone,Felice Giuliante +18 more
TL;DR: This study does not demonstrate a survival benefit from MDT management, but it allows surgery to patients with a more advanced disease as MDT assessment reduces the median duration of chemotherapy and post-operative morbidities.
Journal ArticleDOI
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
J. van de Haar,Xuhui Ma,Salo N. Ooft,Pim W. van der Helm,L.R. Hoes,Sara Mainardi,David J. Pinato,Kristi Sun,Lisa Salvatore,Giampaolo Tortora,Ina Valeria Zurlo,Silvana Leo,Riccardo Giampieri,Rossana Berardi,Fabio Gelsomino,Valeria Merz,Federica Mazzuca,Lorenzo Antonuzzo,Gerardo Rosati,Chara Stavraka,Paul Ross,Maria Grazia Rodriquenz,M. Pavarana,Carlo Messina,Timothy Iveson,Federica Zoratto,Anne Thomas,Elisabetta Fenocchio,Margherita Ratti,Ilaria Depetris,Massimiliano Cergnul,C. Morelli,Michela Libertini,Alessandro Parisi,Michele De Tursi,N. Zanaletti,Ornella Garrone,Janet Graham,R. Longarini,Stefania Gobba,Angelica Petrillo,Emiliano Tamburini,Nicla La Verde,Fausto Petrelli,Vincenzo Ricci,Lodewyk F. A. Wessels,Michele Ghidini,Alessio Cortellini,Emile E. Voest,Nicola Valeri +49 more
TL;DR: In this paper , the authors identified KRAS codon G12 (KRAS G12 ) mutations as a potential biomarker of resistance and showed that they are predictive biomarkers for reduced overall survival (OS) benefit of trifluridine/tipiracil (FTD/TPI) versus placebo.
Journal ArticleDOI
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era?
Ina Valeria Zurlo,Michele A. Basso,Antonia Strippoli,Maria Alessandra Calegari,Armando Orlandi,Alessandra Cassano,Mariantonietta Di Salvatore,Giovanna Garufi,Emilio Bria,Giampaolo Tortora,Carlo Barone,Carmelo Pozzo +11 more
TL;DR: It is suggested that the benefit of pCT might be limited to the intestinal-type, whereas in the diffuse-type survival outcomes were significantly worse in patients receiving pCT compared to those receiving aCT.
Journal ArticleDOI
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi,Alessio Cortellini,Alessio Cortellini,Olga Venditti,Roberto Filippi,Lisa Salvatore,Lisa Salvatore,Giampaolo Tortora,Giampaolo Tortora,Michele Ghidini,Olga Nigro,Fabio Gelsomino,Ina Valeria Zurlo,Claudia Angela Maria Fulgenzi,Pasquale Lombardi,Susana Rosello Keranen,Susana Rosello Keranen,Ilaria Depetris,Riccardo Giampieri,Cristina Morelli,Pietro Di Marino,Francesca Di Pietro,N. Zanaletti,P. Vitale,Ingrid Garajová,Gian Paolo Spinelli,Federica Zoratto,Michela Roberto,Angelica Petrillo,Giacomo Aimar,Leonardo Patruno,Carla D'Orazio,Corrado Ficorella,Claudio Ferri,Giampiero Porzio +34 more
TL;DR: In this article, the authors evaluated post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).